Screener
Tango Therapeutics TNGX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from at-the-market offerings, net of issuance costs | 62,778 | — |
| Payment of transaction costs | (537) | — |
| Proceeds from issuance of common stock under stock plans | 17,605 | 2 |
| Net cash provided by financing activities | 79,846 | 2 |
| Net change in cash, cash equivalents and restricted cash | 45,121 | (11,098) |
| Cash, cash equivalents and restricted cash, beginning of period | 114,846 | 72,097 |
| Cash, cash equivalents and restricted cash, end of period | $159,967 | $60,999 |
| Supplemental cash flow information: |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's financing cash flow?
- Tango Therapeutics (TNGX) reported financing cash flow of $79.85M in Q1 2026.
- How has Tango Therapeutics's financing cash flow changed year-over-year?
- Tango Therapeutics's financing cash flow increased by 3992200.0% year-over-year, from $2K to $79.85M.
- What is the long-term trend for Tango Therapeutics's financing cash flow?
- Over 3 years (2022 to 2025), Tango Therapeutics's financing cash flow has grown at a 416.5% compound annual growth rate (CAGR), from $1.62M to $222.5M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Tango Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude